LXRX Q4 2018 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$693M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-48.3% YoY

Gross Profit

$17M96.7% margin

Operating Income

-$12M-72.4% margin

Net Income

-$17M-98.3% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+149.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$284M

Total Liabilities

$311M

Stockholders' Equity

-$26M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$33M	-48.3%
Gross Profit	$17M	$33M	-49.2%
Operating Income	-$12M	-$31M	+59.8%
Net Income	-$17M	-$28M	+40.9%